Mesothelioma is a rare neoplasm arising from mesothelial cells that line the serous membranes. The pleura is the most commonly affected site, whereas the peritoneum is the second most frequent location, accounting for approximately 10-15% of all mesotheliomas, equivalent to only a few hundred new cases annually in the United States. Unlike pleural … [Read more...]
A Rare Case of Pleural Deciduoid Mesothelioma With Histological, Immunohistochemical, Fluorescent In Situ Hybridization, and Ultrastructural Findings
Abstract: Owing to the rarity of deciduoid mesotheliomas, few studies have reported detailed morphological analyses. Here, we report a case of deciduoid mesothelioma along with cytological, histological, immunohistochemical, fluorescent in situ hybridization (FISH), and electron microscopic findings. The patient was a 75-year-old man with a … [Read more...]
Pleurectomy/Decortication Safe in Select Patients With Pleural Mesothelioma
Pleurectomy/decortication can be completed safely in select patients with pleural mesothelioma with low postoperative mortality, according to findings from a study published in The Annals of Thoracic Surgery. “Our findings show that pleurectomy/decortication can be done safely when patients are carefully selected and surgery is tailored to … [Read more...]
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Treatments: CheckMate 743 Study [Opdivo plus Yervoy treatments have] demonstrated long-term, durable survival benefit as first-line treatment in patients with various solid tumor types. The randomized phase III CheckMate 743 study demonstrated significant overall survival (OS) benefit with [Opdivo plus … [Read more...]
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
Background: Pembrolizumab (anti-PD-1 antibody) plus lenvatinib (multityrosine kinase inhibitor) showed high clinical activity in PEMMELA cohort 1 in patients with pleural mesothelioma pre-treated with platinum-based chemotherapy. This study (cohort 2) aimed to investigate the clinical activity of this combination in patients with pleural … [Read more...]
Pleural Mesothelioma Diagnosis for the Pulmonologist: Steps Along the Way
Background/Objectives: Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis and complex diagnostic pathways. Pulmonologists often play a central role in its initial recognition and investigation. This narrative review synthesizes the current evidence on [mesothelioma diagnosis], with emphasis on imaging, tissue … [Read more...]
Multimodality Therapy Including Pleurectomy/Decortication in Pleural Mesothelioma: Long-Term Outcomes in 152 Consecutive Patients A Retrospective Cohort Study
Objective: Evaluate the long-term outcomes of pleurectomy decortication, systemic chemotherapy and prophylactic radiotherapy in pleural mesothelioma (PM). Summary background data: There is no known cure for PM and cytoreductive surgery remains controversial. Methods: Retrospective analysis of a cohort of patients treated consecutively … [Read more...]
Diffuse Pleural Mesothelioma: A Challenge in Early Diagnosis
Abstract: We present the clinical case of a 58-year-old female patient, a smoker with occupational exposure to respiratory toxins, who was admitted to our clinic following evaluation in an emergency department, where she was diagnosed with a moderate right pleural effusion. Upon admission, the patient exhibited respiratory symptoms, including … [Read more...]
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual checkpoint inhibitor regimens and chemotherapy in combination with immune … [Read more...]
Challenging the Norm: Occurrence of Synchronous Pleural and Peritoneal Mesothelioma in a Female Patient
Abstract: Here, we present a unique case involving a female patient in her 40s with synchronous malignant pleural and peritoneal mesothelioma, despite lacking a history of asbestos exposure. The patient’s initial symptoms included dyspnoea, chest pain, cough, fever, appetite loss, and weight loss over a month. Clinical evaluation led to the … [Read more...]